Jazz Pharmaceuticals (JAZZ) Equity Income (2016 - 2025)
Historic Equity Income for Jazz Pharmaceuticals (JAZZ) over the last 10 years, with Q3 2025 value amounting to -$47000.0.
- Jazz Pharmaceuticals' Equity Income rose 8350.88% to -$47000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$434000.0, marking a year-over-year increase of 7938.24%. This contributed to the annual value of -$1.7 million for FY2024, which is 4483.22% up from last year.
- Per Jazz Pharmaceuticals' latest filing, its Equity Income stood at -$47000.0 for Q3 2025, which was up 8350.88% from -$86000.0 recorded in Q2 2025.
- In the past 5 years, Jazz Pharmaceuticals' Equity Income ranged from a high of $4.2 million in Q1 2021 and a low of -$4.1 million during Q1 2022
- Moreover, its 5-year median value for Equity Income was -$617000.0 (2022), whereas its average is -$857611.1.
- In the last 5 years, Jazz Pharmaceuticals' Equity Income skyrocketed by 218846.15% in 2021 and then tumbled by 61666.67% in 2025.
- Jazz Pharmaceuticals' Equity Income (Quarter) stood at -$3.0 million in 2021, then skyrocketed by 74.13% to -$773000.0 in 2022, then soared by 40.36% to -$461000.0 in 2023, then skyrocketed by 96.53% to -$16000.0 in 2024, then tumbled by 193.75% to -$47000.0 in 2025.
- Its last three reported values are -$47000.0 in Q3 2025, -$86000.0 for Q2 2025, and -$16000.0 during Q4 2024.